Shire: Pipeline, Products, Performance, Potential

Table of Contents

• Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
  • Total Assets by Geographical Area
• Company Strategy
  • Mergers, Acquisitions and Divestitures
    • Acquisitions
    • Divestitures
  • Key Agreements
• Product Performance Forecasts
  • Discontinued Products
• Pipeline Analysis
• Conclusions/Outlook

THER APEUTIC ARE A FOCUS

R&D PIPELINE

CENTRAL NER VOUS SYSTEM

• Marketed Products
  • Adderall/Adderall XR
  • Daytrana
  • Reminyl
  • Vyvanse
  • Others
• R&D Projects
  • Intuniv
  • NRP290
  • SPD465
  • SPD493
• Growth Forecast

GASTROINTESTINAL

• Marketed Products
  • Pentasa
• Growth Forecast

HUMAN GENETIC THERAPIES

• Marketed Products
  • Replagal
  • Elaprase
• R&D Projects
  • GA-GCB
• Growth Forecast

RENAL

• Marketed Products
  • Dynepo
  • Others
• R&D Projects
• Growth Forecast

OTHERS

• Marketed Products
• R&D Projects
  • Juvista
  • NRP409

APPENDIX 1 - FINANCIAL PER FORMANCE

• Full Year Results 2006

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGRE MENTS

• Alba Therapeutics Corp
• Amicus Therapeutics Inc
• Avexa Ltd
• Barr Pharmaceuticals Inc
• Bristol-Myers Squibb
• Genzyme Corporation
• Giuliani farmaceutici/Cosmo Pharmaceutical SpA
• Impax Laboratories Inc
• Johnson & Johnson
• Noven Pharmaceuticals
• Paladin Labs
• Renovo Group plc
• Samaritan Pharmaceuticals

APPENDIX 4 - INFRASTRUCTURE

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIE S/JOINT VENTURES

APPENDIX 6 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• Sales By Business Area
• Operating Income By Business Area
• Total Assets by Business Area
• Sales By Geogrpahic Area
• Recent Product Approvals
• Major Therapeutic Areas And Sales
• Major CNS Products, 2006
• Major Gastrointestinal Products, 2006
• Major HGT Products, 2006
• Major Renal Products, 2006
• Other Products, 2006

Index of Charts

• R&D Expenditure and Capital Expenditure
• Sales By Business Area, 2006
• Operating Income by Business Area
• Sale By Geographic Area
• Top 10 Selling Product Sales (2001A-2011E)
• Top Selling Products, 2006
• Adderall XR Sales (2001A-2011E)
• Daytrana Sales (2001A-2011E)
• Reminyl Sales (2001A-2011E)
• Intuniv Sales (2008E-2012E)
• Pentasa Sales (2001A-2011E)
• Replagal Sales (2001A-2011E)
• Elaprase Sales (2001A-2011E)
• Dynepo Sales (2007E-2011E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity